Abstract. Colon cancer is characterized by invasion and migration. DNA methylation of CpG islands in tumor suppressor genes is considered to be an epigenetic mechanism underlying cancer development. Epigenetic silencing of a gene may be reversed by drugs, including genistein. The present study aimed to determine the effect of genistein on Wnt inhibitory factor 1 (WIF1) and invasion, and migration of colon cancer cells. The viability of HT29 colon cancer cells was suppressed by genistein in a dose dependent manner. Following 72 h of treatment with 10, 20 and 60 µmol/l genistein, increased demethylation of WIF1 was induced in a dose-dependent manner. Additionally, the invasive/migratory abilities of cells treated with genistein decreased in a dose-dependent manner. Reverse transcription-quantitative polymerase chain reaction and western blot analyses were performed to identify the mRNA and protein expression levels of invasion/migration-associated factors. Following treatment with genistein, matrix metalloproteinase (MMP) 2 and MMP9 expression levels decreased, whereas the expression of metalloproteinase inhibitor 1 and E-cadherin increased significantly. In addition, the expression levels of proto-oncogene Wnt-1 (Wnt-1)/β-catenin pathway-associated factors, β-catenin, c-Myc proto-oncogene protein and cyclin D1 decreased in a dose-dependent manner following treatment with genistein. The invasive/migratory abilities of cells transfected with WIF1-small interfering (si) RNA, and those transfected with WIF1-siRNA and treated with genistein, increased notably compared with the control group. The present study demonstrated that genistein was able to inhibit the cell invasion and migration of colon cancer cells by inducing demethylation, and recovering the activity of WIF1 by altering the expression of invasion-associated factors, and components of the Wnt signaling pathway.
Introduction
Colon cancer is one of the most common malignant carcinomas, the morbidity of which is the second highest among gastroenteric tumors worldwide (1) . The majority of patients with colon cancer suffer from hemafecia, diarrhea and pain. Colon cancer affects human health. Due to the late stage of diagnosis and poor efficacy of treatment, the incidence and mortality rates are 8-9% (2). The 5-year survival rate of early-stage colon cancer exceeds 70-90%, although the survival rate of advanced colon cancer is unsatisfactory. National Comprehensive Cancer Network guidelines recommend surgical treatment for patients with primary-stage colon cancer. However, in patients with advanced-stage disease, it is challenging to completely remove the tumor via surgical procedures due to the ubiquitous invasion and migration. Therefore, palliative surgery combined with chemotherapy is more frequently applied (3) . Chemotherapy is given priority among comprehensive treatments (4) . However, anti-drug sensitivity or severe adverse reactions occasionally limit the clinical effectiveness. It is therefore necessary to develop novel drugs exhibiting fewer anti-drug sensitivity effects and adverse reactions. Genistein is a potential drug candidate for the treatment of colon cancer.
The initiation and progression of carcinogenesis occurs when genetic and epigenetic modifications accumulate and interact. DNA methylation of CpG islands in the promoter region of tumor suppressor genes is considered to be an epigenetic mechanism underlying cancer development (4, 5) . As a highly conserved metabolism-associated pathway, the Wnt signaling pathway is involved in metabolic processes, including embryonic development, cell proliferation, metastasis and differentiation. The Wnt signaling pathway is inactive in normal cells, and the abnormal activation may induce tumor development. Wnt inhibitory factor 1 (WIF1) is a tumor suppressor, which interacts with Wnt protein to inhibit the canonical and non-canonical Wnt pathways. It has been reported that silencing of WIF1 via methylation is associated with cancers, such as colon cancer (6) . A previous study additionally reported that WIF1 inhibited the Wnt signaling pathway by inhibiting β-catenin accumulation, suppressed esophageal cancer and decreased the expression of E2F transcription factor 1, cyclin D1 and c-Myc proto-oncogene protein (c-Myc) to promote the apoptosis of hepatoma cells (7) .
Recent studies demonstrated that methylation-mediated epigenetic silencing of genes may be reversed by drugs (8, 9) . Genistein, a soy-derived isoflavone, is reported to upregulate the mRNA expression of a number of tumor suppressor genes, to antagonize function of growth stimulating factors and to inhibit cellular malignancy. Genistein has a broad-spectrum anti-cancer effect on breast, prostate, esophageal, pancreatic, gastric and colon cancer, and metrocarcinoma, lymphoma and neuroblastoma; and therefore, it is becoming a novel therapy for the treatment of tumors (10) (11) (12) . However, whether genistein is able to upregulate the mRNA expression of WIF1 through demethylation in colon cancer remains to be elucidated.
The present study investigated the effect of treatment with genistein on WIF1 in colon cancer cells, particularly on cell invasion and migration. The present study suggested a mechanism underlying the genistein-mediated demethylation of the WIF1 promoter region, and its influence on downstream molecular factors in the associated pathways. The results of the present study may contribute to the treatment of colon cancer.
Materials and methods
Patients and tissue samples. Written informed consent was obtained from all participants prior to the present study. A total of 52 patients (36-79 years old; median age, 55 years), 32 males and 20 females, with colon cancer from Changzhou No. 2 People's Hospital (Changzhou, China) were included in the present study, from November 2015 to November 2016. The present study included two patients with well-differentiated tumors, 31 patients with moderately-differentiated tumors and 19 patients with poorly-differentiated tumors. Of those patients, a total of nine were in the T1+T2 stage, 22 patients were in the T3 stage and 21 patients were in the T4 stage. Preoperative clinical and pathological follow-up data were completed by all patients. All tissue samples of patients were collected according to procedures approved by the institutional review board of the independent ethics committee of Changzhou No. 2 People's Hospital. Adjacent normal colon tissues were also collected as negative controls. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analyses were performed to detect the mRNA and protein expression levels of WIF1 in colon cancer tissues and adjacent normal colon tissues. Detailed procedures are described in the designated sections below.
Cell culture. Human colon mucosal epithelial cells NCM460 and colon cancer cell lines (HT29, SW620, LOVO, HCT116) were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) with 1% penicillin/streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C with 5% CO 2 . Cells in the logarithmic phase were used for subsequent experimentation.
RT-qPCR and western blot analyses were performed to detect the mRNA and protein expression of WIF1 in the above colon cancer cell lines and the normal colon cell line NCM1460. RT-qPCR and western blot analyses were performed to detect the mRNA and protein expression of WIF1 in HT29 colon cancer cells and genistein-treated cells (10, 20 and 60 µmol/l).
Cell viability assay.

Methylation specific PCR (MSP).
Following a 72 h-treatment with 10, 20 and 60 µmol/l genistein independently, HT29 cells (1.5x10 4 cells/sample) were subjected to bisulfite conversion using the EZ DNA Methylation-Startup kit (Zymo Research Corp., Irvine, CA, USA), according to the manufacturer's protocol. Subsequently, 30 ng converted DNA of each sample was used for the MSP amplification. The WIF1 promoter region was identified using the online software Cell invasion and migration assay. Cell invasion and migration assays were performed using 24-well Transwell chambers with polycarbonate filters (Corning Incorporated, Corning, NY, USA). Matrigel chambers (BD Biosciences, Franklin Lakes, NJ, USA) were applied to evaluate the effect of genistein (10, 20 and 60 µmol/l) on invasiveness, according to the manufacturer's protocol. Cells treated with genistein for 48 h were collected and resuspended in serum-free medium and transferred to diluted Matrigel chambers (5x10 4 cells/well). The chambers were incubated for 24 h prior to examination, with the bottom chambers containing culture medium with 10% FBS. The invaded cells on the lower surface that passed through the filter were stained using 0.1% crystal violet for 30 min at room temperature. Finally, invading cells were counted in five randomly-selected high power fields under a light microscope (Olympus Corporation, Tokyo, Japan, magnification, x100) and the cell number was calculated. A cell migration assay was performed using the same procedure as described above for the cell invasion assay, although cell medium without Matrigel was used.
RT-qPCR and western blot analyses were performed to detect the mRNA and protein expression of the invasion/migration-associated factors E-cadherin, matrix metalloproteinase (MMP) 2, MMP9, tissue inhibitor of metalloproteinase inhibitor 1 (TIMP1), β-catenin, c-Myc proto-oncogene protein (c-Myc) and cyclin D1, serving a role in the Wnt/β-catenin signaling pathway.
Small interfering (si)RNA transfection. siRNA transfection was performed to validate the effect of WIF1 on tumor invasion and the effect of treatment with genistein on tumor suppression. siRNA-WIF1 was designed and synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). For the siRNA transfection, cells were seeded onto 12-well cell culture plates at an initial density of 6x10 4 cells/well. When cells were 70% confluent, they were transfected with 1 µg WIF1 siRNA (siWIF1 group) or nonspecific siRNA (mock group) with FlexiTube siRNA Premix transfection reagent (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer's protocols. HT29 cells without any treatment served as the control group. The following siRNA sequences were used: siWIF1, 5'-CUC AUA GGA UUU GAA GAA G-3'; and nonspecific siRNA, 5'-UCA CUG CGC UCG AUG CAG UTT-3'.
RT-qPCR and western blot analyses were performed to measure the interference efficiency 48 h following transfection. Cell invasion/migration assays were performed as a forentioned to evaluate the effect of siWIF1 transfection among the control, mock, siWIF1 and siWIF1+genistein (siWIF1 group treated with 60 µmol/l genstein) groups. The above experiments were performed independently.
RT-qPCR analysis. Total RNA was extracted from cells by ZR RNA MiniPrep kit (Zymo Research Corp., Irvine, CA USA), and reverse-transcribed into cDNA using a first strand cDNA kit (Sigma-Aldrich; Merck KGaA), according to the manufacturer's protocol. The following thermocycling conditions were used for the PCR: Initial denaturation for 30 sec at 95˚C; 40 cycles of denaturation at 95˚C for 5 sec, annealing/extension at 60˚C for 30 sec and final extension at 72˚C for 10 min. An ABI 7300 thermocycler (Applied Biosystems; Thermo Fisher Scientific, Inc.) and the SYBR Premix Ex Taq kit (Takara Biotechnology Co., Ltd., Dalian, China) were used. The quantification was identified by 2 -ΔΔCq (13) . Primer sequences used for the PCR are listed in Table I .
Western blot analysis. Tissues or cells were lysed by lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 0.02% NaN2, 100 µg/ml phenylmethanesulfonyl fluoride, 1 µg/ml aprotinin, and 1% Triton X-100) and the supernatant was collected. Protein concentrations were determined using a bicinchoninic acid assay (Beyotime Institute of Biotechnology, China). A total of 20 µg proteins were subjected to 10% SDS-PAGE and electroblotted onto polyvinylidene fluoride membranes (PVDF). Following blocking with 5% skimmed dried milk in PBS for 1 h at room temperature, blotting membranes were probed overnight at 4˚C with the following primary antibodies: Rabbit anti-WIF1 (1:2,000; ab186845; Abcam, Cambridge, UK), anti-E-cadherin (1:500; ab15148; Abcam), anti-MMP2 (1:1,000; ab92536; Abcam), anti-MMP9 (1:1,000; ab38898; Abcam), anti-TIMP1 (1:1,000; ab61224; Abcam), anti-β-catenin (1:5,000; ab16051; Abcam), anti-C-Myc (1:1,000; ab39688; Abcam), and anti-Cyclin D1 (1:2,000; ab226977; Abcam), GAPDH (1:2,000; ab9485; Abcam). GAPDH was used for the loading control. Subsequently, the membranes were probed with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies: Goat anti-rabbit immunoglobulin G H&L HRP (1:5,000; ab205718 and ab6721; Abcam) for 1 h at room temperature. The PVDF membranes were exposed to X-ray film and immunoreactive bands were detected by enhanced chemiluminescence detection system reagents (Amersham; GE Healthcare, Chicago, IL, USA). Lab Works Image Acquisition and Analysis software (Visionworks ® LS, UVP, LLC, Phoenix, AZ, USA) was used to quantify band intensities.
Statistical analysis. Data are presented as the mean ± standard deviation of three independent experiments. Statistical analysis was performed using SPSS software (version 13.0; SPSS, Inc., Chicago, IL, USA) and data were analyzed using one-way analysis of variance, followed by Dunnett's test. P<0.05 was considered to indicate a statistically significant difference.
Results
Low expression of WIF1 in colon cancer tissues and cell lines.
To verify the biological role of WIF1 in colon cancer, the mRNA and protein expression levels of WIF1 in colon cancer tissues and colon cancer cell lines (HT29, SW620, LOVO, HCT116) were detected by RT-qPCR and western blot analyses. The expression of WIF1 in the adjacent normal colon tissues and in the colon epithelial cell line NCM460 was detected as the control. The results demonstrated that the mRNA and protein expression of WIF1 was decreased in colon cancer tissues compared with the adjacent normal tissues (both P<0.01; Fig. 1A-C) . The mRNA and protein expression of WIF1 was additionally downregulated in colon cancer cells (HT29, SW620, LOVO and HCT116), compared with normal colon NCM460 cells (Fig. 1D-F) . The above results indicated that downregulated expression of WIF1 may be associated with the initiation and/or progression of colon cancer. The HT29 cell line was selected for subsequent experiments as it exhibited the lowest expression of WIF1, compared with the other cell lines included in the present study.
Effect of genistein on HT29 cell viability, and WIF1 expression and promoter methylation. The effect of genistein on HT29 cell viability was measured by CCK8 assay. Cell viability was suppressed in the genistein-treated groups in a dose-dependent manner compared with the control group ( Fig. 2A) . Cell viability was respectively 66, 51, 44 and 38% of the control when treated with 10, 20, 40 and 60 µmol/l genistein for 72 h (all P<0.01). HT29 cells treated with 10, 20 and 60 µmol/l genistein respectively for 72 h were subjected to the subsequent experimentation.
RT-qPCR and western blot analyses demonstrated that the mRNA and protein expression of WIF1 notably increased in genistein-treated cells in a dose-dependent manner (Fig. 2B-D) . The above results confirmed that genistein could recover the expression and function of WIF1 to inhibit cell viability.
As detected by MSP, following 72 h of treatment with 10, 20 and 60 µmol/l genistein, levels of demethylated WIF1 increased compared with the levels of methylated WIF1. These effects occurred in a dose-dependent manner, compared withthe respective control groups (Fig. 2E) . The above results indicated that the role served by genistein in colon cancer may be associated with demethylation of WIF1, to recover its tumor suppressor function.
Effect of genistein on HT29 cell invasion and migration.
The invasive and migratory ability of HT29 cells treated with genistein was identified by Transwell assay. The results of the assay demonstrated that the invasive/migratory abilities of cells treated with 10, 20 and 60 µmol/l genistein for 72 h decreased notably in a dose-dependent manner, compared with the control group. Invasion rates in groups treated with 10, 20 and 60 µmol/l genistein were ~75, 66 and 58%, respectively, compared with the control group (Fig. 3A and B) . Migration rates in groups treated with 10, 20 and 60 µmol/l genistein were ~82, 69 and 53%, respectively, compared with the control group ( Fig. 3C and D) .
Effect of genistein on the expression of factors associated with cell invasion and the Wnt/β-catenin signaling pathway in HT29 cells.
RT-qPCR and western blot analyses were performed to detect the mRNA and protein expression of invasion/migration-associated factors, including E-cadherin, MMP2, MMP9 and TIMP1, and factors associated with the Wnt/β-catenin signaling pathway: β-catenin, c-Myc and cyclin D1.
The results of the present study demonstrated that the mRNA and protein expression levels of E-cadherin and TIMP1 increased significantly, while the expression levels of MMP2 and MMP9 decreased significantly, in a dose-dependent manner in genistein-treated cells (72 h), compared with the control group (Fig. 4A-C) . A significant dose-dependent decrease in mRNA and protein expression levels of β-catenin, c-Myc and cyclin D1 was observed in cells treated with genistein, compared with the control group (Fig. 4D-F) . The results of the present study indicated that the inhibitory properties of genistein on HT29 cell invasion and migration may be associated with the expression of invasion/migration-associated factors, including E-cadherin, MMP2, MMP9 and TIMP1, and factors associated with the Wnt/β-catenin signaling pathway (β-catenin, c-Myc and cyclin D1).
Effect of WIF1-siRNA transfection on HT29 cell invasion and migration. WIF1 knockdown and the interference efficiency were identified using RT-qPCR and western blot analyses. Transfection of siRNA-WIF1 resulted in a significant decline in WIF1 mRNA and protein expression levels in the siRNA-WIF1 group compared with the control and mock groups, which confirmed that siRNA-WIF1 was effective in silencing the expression of WIF1 (all P<0.01; Fig. 5A-C) .
The invasive and migratory abilities of the siWIF1, siWIF1+genistein, mock and HT29 control groups were identified by Transwell assay. The results of the above experiment demonstrated that the invasive/migratory abilities of the siWIF1and siWIF1+genistein groups increased significantly, compared with the control group and mock group (all P<0.05). The invasion rate of the siWIF1 and siWIF1+genistein groups was 139 and 122%, respectively, compared with the control group ( Fig. 5D and E) . The migration rates of the siWIF1 and siWIF1+genistein groups were 142 and 125%, respectively, compared with the control group ( Fig. 5F and G) . It was confirmed that genistein was able to partly reverse the function of siWIF1 in promoting cell invasion/migration.
Discussion
Colon cancer is one of the most common malignant carcinomas, demonstrating elevated invasion and migration rates (10) . DNA methylation of CpG islands inpromoter regions of tumor suppressor genes is considered to be an epigenetic mechanism underlying cancer development (11) . Abnormal activation of the Wnt signaling pathway could induce tumor development (12) . Previous studies reported that silencing of WIF1 via methylationis associated with colon cancer (5,14,15) . Table I . Primers used for reverse transcription-quantitative polymerase chain reaction.
Primer sequence ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Gene
Forward (5'→3') Reverse (5'→3')   WIF1  ATCATCTTCTTAACTGGCATTGTG  AAAAATAAAAAAAACACGCT  E-cadherin  CTGAAGTGACTCGTAACGAC  CATGTCAGCCAGCTTCTTGAAG  TIMP1  TCGTCATCAGGGCCAAGTTC  TCCACAAGCAATGAGTGCCA  MMP2  ATGCAGTGGGGGCTTAAGAA  TCTGGGGCAGTCCAAAGAAC  MMP9  CATCCGGCACCTCTATGGTC The primary aim of the present study was to elucidate the molecular mechanism underlying genistein-mediated inhibition of invasion and migration of colon cancer associated with WIF1 demethylation. Preliminary observations Low expression of WIF1 may induce abnormal activation of the Wnt signaling pathway, promoting cell proliferation and resulting in tumor development (16, 17) . In the present study, the proliferation of HT29 colon cancer cells treated with genistein was inhibited in a dose-dependent manner. The mRNA and protein expression levels of WIF1 increased in HT29 cells treated with genistein in a dose-dependent manner, suggesting that the function of genistein on cell proliferation was associated with the regulation of WIF1 expression. In order to further elucidate the mechanism underlying the modulation of expression of WIF1 in colon cancer cells, an MSP assay was performed to evaluate methylation levels in the promoter region of the WIF1 gene. Decreased methylation levels in the group treated with genistein, compared with the control group indicated that genistein-mediated upregulation of WIF1 expression maybe associated with the demethylation of CpG islands.
A number of factors are involved in the process of tumor development. The Transwell assay performed in the present study demonstrated that genistein inhibited the migration and invasion of HT29 cells in a dose-dependent manner.
It was additionally demonstrated that the mechanism underlying the above observations was associated with the regulation of invasion/migration-associated factors. MMP is a family of enzymes regulating the proteolysis of extracellular matrix-associated structural proteins, dysregulation of MMPs in cells can result in the degradation of the histological barrier that normally prevents cell invasion and migration (18) (19) (20) . MMPs serve a number of roles in tumor cell invasion and migration, and have been investigated in a recent study (21) . Type IV collagenases are a sub-family of MMPs that includes two members, glycosylated MMP9 and non-glycosylated MMP2. Previous studies demonstrated that Type IV collagenases are implicated in tumor cell invasion and migration processes (22, 23) . MMPs are controlled by endogenous tissue specific inhibitors, also known as tissue inhibitors of metalloproteinases (TIMPs) (24) . TIMP1 can inhibit tumor progression by suppressing MMP9-mediated release of vascular endothelial growth factor from the matrix. E-cadherin, a family member of Ca 2+ -dependent transmembrane glycoproteins, is an important tumor suppressor participating in intercellular signal transduction (25). E-cadherin is able to conjugate to β-catenin in the cytoplasm and inhibit its function in the Wnt signaling pathway. The results of the present study demonstrated that treatment with genistein resulted in decreased expression of MMP9 and MMP2, and increased expression of TIMP1 and E-cadherin in HT29 cells, compared with the control group. The above results indicated that genistein regulates tumor invasion and migration by influencing the expression levels of MMP2, MMP9, TIMP1 and E-cadherin. The Wnt/β-catenin signaling pathway is involved in growth-associated processes and tumor development. WIF1 is an inhibitor of the Wnt/β-catenin signaling pathway and, therefore, silencing of WIF1 may activate the pathway and induce tumor development (26) . β-catenin is a scaffold protein linking the cytoplasmic tail of classical cadherins of the endothelium to the actin cytoskeleton. Upregulation of β-catenin may cause tumor metastasis (27) . Cyclin D1 is a cell cycle-related factor associated with G1/S stage transition. C-Myc encodes phosphorylated proteins, which facilitate cell proliferation and differentiation (28) . Cyclin D1 and c-Myc are downstream target genes of the Wnt/β-catenin signaling pathway (29) . The mRNA and protein expression of β-catenin, c-Myc and cyclin D1 decreased in HT29 cells treated with genistein, compared with the control group. It may be hypothesized that demethylation of WIF1 inhibited tumor progression by downregulating the expression of factors associated with the Wnt/β-catenin signaling pathway (β-catenin, c-Myc and cyclin D1).
Following transfection with WIF1-siRNA, the mRNA and protein levels of WIF1 in siWIF1 cells decreased markedly. The invasive and migratory abilities of the siWIF1 and siWIF1+genistein groups increased markedly compared with the control and mock groups, and genistein was able to partly reverse the function of siWIF1 in promoting cell invasion/migration.
In conclusion, the present study demonstrated that the expression of WIF1 was suppressed by methylation of CpG islands in the promoter region, in human colon cancer tissues and cells. Additionally, genistein recovered the expression of WIF1 in the HT29 colon cancer cell line via demethylation of WIF1, and suppressed tumor cell invasion and migration. The above observations may be associated with the regulation of cell invasion and migration-associated genes, including MMP9, MMP2, TIMP1, E-cadherin, β-catenin, c-Myc and cyclin D1. Further in vivo studies are required to confirm the results of the present study. Novel evidence may, in the future, confirm the administration of genistein to be an effective treatment for patients with colon cancer.
